17.11.2024, 1143 Zeichen

Valneva: Valneva SE, an Austrian/French specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive worldwide license from LimmaTech.
Valneva: weekly performance: -9.69%

FACC: The continued strong growth of the aviation industry and the associated high demand for passenger aircraft continues in the third quarter of 2024. FACC AG is benefiting disproportionately strong from this growth trajectory and was able to increase its revenue by +25.1 % to EUR 642.6 million in the first nine months of the 2024 financial year (previous year: EUR 513.9 million). EBIT of EUR 21.8 million more than quadrupled year-on-year (previous year: EUR 5.0 million).
FACC: weekly performance: 7.49%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (13/11/2024)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S18/13: Marco Reiter

Bildnachweis

Aktien auf dem Radar:Frequentis, Porr, VIG, Addiko Bank, Pierer Mobility, RHI Magnesita, ATX Prime, Strabag, Mayr-Melnhof, SBO, Lenzing, CPI Europe AG, EVN, CA Immo, AT&S, Andritz, Wienerberger, Verbund, ATX TR, ATX, voestalpine, Österreichische Post, Marinomed Biotech, Erste Group, FACC, Polytec Group, Rosenbauer, UBM, Bawag, DO&CO, Kapsch TrafficCom.

---